The company says patients currently have to self-administer large volumes of cannabidiol (CBD) to achieve a helpful therapeutic outcome.
The partnership grants dsm-firmenich global access to ZERION AS’s Dispersome technology, developed to significantly increase the bioavailability of oral CBD compared to commercially available CBD oils. The companies say that not only will the collaboration inspire a new generation of patient-first cannabinoid therapies, but it also enhances dsm-firmenich’s end-to-end capabilities in the promising cannabinoid space.
dsm-firmenich says the limited oral bioavailability of cannabinoid molecules, like CBD, is a known barrier to unlocking their full potential. The new partnership aims to change that by granting dsm-firmenich’s formulation expert center exclusive access to Zerion A/S’s Dispersome technology. The IP-protected technology has enabled the creation of CBD formulations with three to four times higher drug loading compared to existing commercial products.
Dr. Zdravka Misic, innovation manager dsm-firmenich, says: “From the very beginning of our cannabinoid journey, the patient has always been front of mind. At present, too many patients have to administer large volumes of CBD in oil to achieve a positive therapeutic outcome.
“However, with our formulation expertise and Zerion A/S’s innovative technology, we have been able to achieve an optimal balance between API loading, physical and chemical stability and CBD…
